Study Stopped
Unable to recruit participants into trial
Excimer Laser, Serum Markers & Psoriasis
Effects of UVB Excimer Laser on Serum Inflammatory Markers in Patients With Psoriasis
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The overall aims for this study are to determine whether UVB excimer laser treatment of psoriasis affects serum inflammatory markers, and to assess hyperpigmentation and erythema with excimer laser treatment. The investigators hypothesize that treatment of psoriasis with UVB delivered via 308 nm excimer laser will decrease the levels of serum inflammatory markers. The investigators hypothesize that treatment will decrease plaque erythema and will result in minimal hyperpigmentation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Sep 2013
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2013
CompletedFirst Submitted
Initial submission to the registry
June 13, 2014
CompletedFirst Posted
Study publicly available on registry
June 17, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2017
CompletedJuly 16, 2021
July 1, 2021
3.5 years
June 13, 2014
July 9, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in serum inflammatory markers
Change in CRP, MPO, S100 and Resistin levels from screening to final visit.
23 visits (~12 weeks)
Secondary Outcomes (4)
Objective measure of hyperpigmentation
23 visits (~12 weeks)
Objective measure of erythema
23 visits (~12 weeks)
Improvement in Psoriasis based on PASI assessment
23 visits (~12 weeks)
Improvement in psoriasis based on PGA
23 visits (~12 weeks)
Study Arms (1)
Excimer laser
EXPERIMENTALExcimer laser treatment
Interventions
Excimer laser irradiation twice a week for up to 20 treatments.
Eligibility Criteria
You may qualify if:
- Age 18 years and older
- Male or female with diagnosis of psoriasis
- Psoriasis involvement of 5-15% BSA
- Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic agents, etc) for at least 4 weeks
- Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks
- Fitzpatrick Skin Types I-VI
You may not qualify if:
- Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
- Any suspicion that the psoriasis is of the photosensitive variant.
- Any medical condition that could be aggravated or may cause extreme discomfort during the study period.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospitals Cleveland Medical Centerlead
- Photomedexcollaborator
Study Sites (1)
University Hospitals Cleveland Medical Center (Concord Site)
Concord, Ohio, 44077, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Margaret Bobonich, NP
University Hospitals Cleveland Medical Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 13, 2014
First Posted
June 17, 2014
Study Start
September 1, 2013
Primary Completion
March 1, 2017
Study Completion
March 1, 2017
Last Updated
July 16, 2021
Record last verified: 2021-07